Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab

Pediatric Research

Volumn 69, Issue 3, 2011, Pages 243-248

  Kosmač, Miha ^a   Avčin, Tadej ^b   Toplak, Nataša ^b   Simonini, Gabriele ^c   Cimaz, Rolando ^c   Šerbec, Vladka Čurin ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DRUG ANTIBODY; EPITOPE; INFLIXIMAB; INFLIXIMAB ANTIBODY; LEFLUNOMIDE; METHOTREXATE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CONFORMATION; DRUG INHIBITION; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RHEUMATIC DISEASE; SCHOOL CHILD; TWO DIMENSIONAL ELECTROPHORESIS;

ADOLESCENT; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BINDING SITES; CHILD; CHILD, PRESCHOOL; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULIN G; PROTEIN CONFORMATION; RHEUMATIC DISEASES;

EID: 79951607958     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1203/PDR.0b013e318208451d     Document Type: Article

References (27)

1. Ravelli A, Martini A 2007 Juvenile idiopathic arthritis. Lancet 369:767-778
2. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Apaz M, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur A, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, Joos R, Zulian F, McCurdy D, Myones BL, Nagy K, Reuman P, Szer I, Travers S, Beutler A, Keenan G, Clark J, Visvanathan S, Fasanmade A, Raychaudhuri A, Mendelsohn A, Martini A, Giannini EH, Organisation PR, Group PR 2007 A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56:3096-3106 (Pubitemid 47502757)
3. Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A, Salmaso A, Fantini F 2005 Efficacy of repeated intravenous infusions of an anti-tumor-necrosis-factor-alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum 52:548-553 (Pubitemid 40216319)
4. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN 2008 Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin Rheumatol 27:67-76 (Pubitemid 350182680)
5. Lahdenne P, Vähäsalo P, Honkanen V 2003 Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open-label study. Ann Rheum Dis 62:245-247 (Pubitemid 36238089)
6. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, Ghrayeb J 1993 Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30:1443-1453
7. Le J, Vilcek J, Dadonna P, Ghrayeb J, Knight D, Siegel SA 1997 Methods of treating TNF-alpha-mediated Crohn's disease using chimeric anti-TNF antibodies. US Patent 5,656,272
8. Gerloni V, Pontikaki I, Gattinara M, Fantini F 2008 Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open, monocentric, long-term prospective study of 163 patients. Ann Rheum Dis 67:1145-1152
9. Koren E, Smith HW, Shores E, Shankar G, Finco-Kent D, Rup B, Barrett Y, Devanarayan V, Gorovits B, Gupta S, Parish T, Quarmby V, Moxness M, Swanson SJ, Taniguchi G, Zuckerman LA, Stebbins CC, Mire-Sluis A 2008 Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 333:1-9
10. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P 2003 Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348:601-608 (Pubitemid 36204954)
11. Bourdage JS, Lee TN, Taylor JM, Willey MB, Brandt JT, Konrad RJ 2005 Effect of double antigen bridging immunoassay format on antigen coating concentration dependence, and implications for designing immunogenicity assays for monoclonal antibodies. J Pharm Biomed Anal 39:685-690 (Pubitemid 41196083)
12. Mortz E, Krogh TN, Vorum H, Görg A 2001 Improved silver-staining protocols for high-sensitivity protein identification using matrix-assisted laser desorption/ ionization time-of-flight analysis. Proteomics 1:1359-1363 (Pubitemid 33587891)
13. Kapoor KN, Barry DT, Rees RC, Anthony Dodi I, McArdle SE, Creaser CS, Bonner PL 2009 Estimation of peptide concentration by a modified bicinchoninic acid assay. Anal Biochem 393:138-140
14. Bingham CO 2008 Emerging therapeutics for rheumatoid arthritis. Bull NYU Hosp Jt Dis 66:210-215
15. Haines KA 2007 Juvenile idiopathic arthritis: therapies in the 21st century. Bull NYU Hosp Jt Dis 65:205-211 (Pubitemid 351412134)
16. Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, Silverman ED, Balogh Z, Henrickson M, Davidson J, Foeldvari I, Imundo L, Simonini G, Opper-mann J, Xu S, Shen YK, Visvanathan S, Fasanmade A, Mendelsohn A, Martini A, Giannini EH, Paediatric Rheumatology INternational Trials Organization (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG) 2010 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 69:718-722
17. Aarden L, Ruuls SR, Wolbink G 2008 Immunogenicity of anti-tumor-necrosis- factor antibodies-towards improved methods of anti-antibody measurement. Curr Opin Immunol 20:431-435
18. Van Der Laken CJ, Voskuyl AE, Roos JC, Stigter van Walsum M, de Groot ER, Wolbink G, Dijkmans BA, Aarden LA 2007 Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 66:253-256 (Pubitemid 46226064)
19. Finckh A, Dudler J, Wermelinger F, Ciurea A, Kyburz D, Gabay C, Bas S 2010 Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. Joint Bone Spine 77:313-318
20. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M 1998 Therapeutic efficacy of multiple intravenous infusions of anti-tumor-necrosis-factor-alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552-1563 (Pubitemid 28459913)
21. Dhingra N, Morgan J, Dick AD 2009 Switching biologic agents for uveitis. Eye (Lond) 23:1868-1870
22. St. Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC 2002 The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:1451-1459 (Pubitemid 34620190)
23. Scott DW, De Groot AS 2010 Can we prevent immunogenicity of human protein drugs? Ann Rheum Dis 69:i72-i76
24. Nagata S, Pastan I 2009 Removal of B-cell epitopes as a practical approach for reducing the immunogenicity of foreign-protein-based therapeutics. Adv Drug Deliv Rev 61:977-985
25. Carter JM, Loomis-Price L 2004 B cell epitope mapping using synthetic peptides. Curr Protoc Immunol Chapter 9: Unit 9.4
26. Heuzenroeder MW, Barton MD, Vanniasinkam T, Phumoonna T 2009 Linear B-cell epitope mapping using enzyme-linked immunosorbent assay for libraries of overlapping synthetic peptides. Methods Mol Biol 524:137-144
27. Irving MB, Craig L, Menendez A, Gangadhar BP, Montero M, van Houten NE, Scott JK 2010 Exploring peptide mimics for the production of antibodies against discontinuous protein epitopes. Mol Immunol 47:1137-1148